

DISCLAIMER AND FORWARD-LOOKING STATEMENT

The material contained herein is of a general nature & has only been prepared as a presentation aid. This presentation does NOT contain all of the information that may be required for evaluating Adherium Limited ACN 605 352 510 (Adherium or the Company), its assets, prospects or potential opportunities.

This presentation may contain budget information, forecasts & forward-looking statements in respect of which there is NO guarantee of future performance & which of themselves involve significant risks (both known & unknown). Actual results & future outcomes will in all likelihood differ from those outlined herein.

Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" & similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding market size, future results, regulatory approvals, production targets, sales, staffing levels etc. All of such statements are subject to risks & uncertainties, many of which are difficult to predict & generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information & statements.

These risks & uncertainties include, but are not limited to:

- i. the possible delays in & the outcome of product development
- ii. risks relating to possible partnering or other like arrangements
- iii. the potential for delays in regulatory approvals
- iv. the unknown uptake & market penetration of any potential commercial products &
- v. other risks & uncertainties related to the Company's prospects, assets / products & business strategy. This is particularly the case with companies such as Adherium which operate in the field of developing & commercializing medical devices & related services. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, & we do not undertake any obligation to revise & disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Additionally, there are a number of factors, both specific to Adherium & of a general nature, which may affect the future performance of Adherium. There is no guarantee that Adherium will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward-looking statements will be realised.





UNMET NEED: SIGNIFICANT BURDEN TO HEALTH SYSTEMS AND RESPIRATORY PATIENTS FROM PREVENTABLE GAPS IN INHALER TECHNIQUE AND ADHERENCE

PREVENTABLE COPD THIRD UP TO 92% OF 80% OF **HOSPITALIZATION LEADING CAUSE ASTHMA PATIENTS ASTHMA-RELATED COST US HEALTH OF DEATH USE THEIR HOSPITALIZATIONS** SYSTEM ALONE **GLOBALLY INHALER IN AUSTRALIA ARE** \$34B ANNUALLY **INCORRECTLY PREVENTABLE**



OUR SOLUTION – THE HAILIE PLATFORM

SETS NEW PREVENTATIVE TREATMENT STANDARD

- > INTEGRATED DATA INSIGHTS
- > ENABLING DOCTOR REIMBURSEMENT
- > PATIENT BETTER QUALITY OF LIFE
- > AT ZERO TO LITTLE PATIENT EXPENSE

HAILIE SENSOR

Compatible today with 91% of the US top 20 inhaler medication brands by sales volume.

Only US FDA 510(k) cleared sensor on the market to offer respiratory flow rate data and track adherence.

HAILIE PORTAL & SDK/API

Captures data for patient management, digital health records, clinical reference and enables reimbursement for doctors and partners.

Symbicort

·111 @

Users

Prescribed

Taken

2 2 4

Last Synced: 5 minutes ago

Last 7 Days: 90%

HAILIE APP

Tracks medication usage and allows patients to enable audio and visual reminders to take medication.








A FLEXIBLE CHANNEL PARTNER PLATFORM

PATIENT TOOLS






PROFESSIONAL



CLINICAL ECOSYSTEM





HAILIE SENSOR PORTFOLIO WITH US FDA 510(k) CLEARANCES

New, next generation sensors with physiological data capability









Trelegy * Ellipta*

































TIME IS NOW FOR REMOTE PATIENT MONITORING: ADHERIUM PERFECTLY PLACED


Financial incentives for US doctors, hospital systems, medical groups

- Two new US reimbursement codes for doctors to get paid:
 - Remote Physiological Monitoring (for respiratory flow rate) published 2019
 - Remote Therapeutic Monitoring (for inhaler usage) published 2022
- US\$1,270 US\$1,760/year doctor reimbursement per patient
 - \$55.72/patient/mo for generating and transmitting data)
 - Leverage staff for US\$50.18 for first 20 minutes and US\$40.84 for second 20 minutes per patient per month
- Adherium sensors engineered for reimbursement requirements



REVENUE BY GENERATING AND TRANSMITTING PATIENT DATA AND INSIGHTS

US ASTHMA AND COPD PATIENTS



ADHERIUM TARGET REVENUE MODEL

- Saas AND DATA FEES
- > US\$15-30/MO/PATIENT
- GENERATING AND TRANSMITTING PATIENT DATA



PARTNER OF CHOICE: AN ACCELERATED GROWTH STRATEGY



NOW: DELIVERING ON PRODUCT DEVELOPMENT MILESTONES

Expand platform with new, next-generation sensors:

- CY22: FDA 510(k)
- Quality system validation and verification
- Market release

Progress drug agnostic coverage of the US branded inhaler medications



NEXT: FOCUS ON RECURRING REMOTE PATIENT MONITORING REVENUE

Establish new commercial partnerships

Engage with well-respected **US hospital system** to prove and then expand to scale

up and cash flow positive

Data sets mined for clinical insights



FUTURE: DEVELOP DATA INSIGHTS AND DATA SCIENCE PORTFOLIO

Acquire "real-world" clinical outcome data

Create respiratory predictive analytics functionality

Develop pathway for **Software as a Medical Device** (SaMD) and predictive algorithms



